What is Rapid Micro Biosystems?
Rapid Micro Biosystems specializes in mission-critical automation solutions designed to streamline the manufacturing and release of complex healthcare products, including biologics, vaccines, and cell and gene therapies. Its flagship Growth Direct System replaces antiquated, manual microbial quality control (MQC) testing with a high-efficiency, automated platform. By moving MQC testing directly to the manufacturing floor, the company enables pharmaceutical operators to achieve faster results, superior data integrity, and enhanced regulatory compliance. Headquartered in Lowell, Massachusetts, with an expansive international footprint, the company serves as a vital partner to the world's largest pharmaceutical manufacturers, ensuring the safe and consistent supply of essential medical products.
How much funding has Rapid Micro Biosystems raised?
Rapid Micro Biosystems has raised a total of $396.7M across 10 funding rounds:
Series B
$32.6M
Private Equity
$6M
Debt
$6M
Series C
$25M
Other Financing Round
$60M
Other Financing Round
$120M
Other Financing Round
$81M
Debt
$45M
Series B (2013): $32.6M supported by Longitude Capital, Kleiner Perkins Caufield & Byers, TPG Biotech, Quaker Partners, and TVM Capital
Private Equity (2014): $6M featuring Kleiner Perkins Caufield & Byers, TPG Biotech, TVM Capital, Quaker Partners, and Longitude Capital
Debt (2015): $6M, investors not publicly disclosed
Series C (2015): $25M with participation from Richard K. Mellon and Sons, Quaker Partners, TVM Capital, Hepalink, Kleiner Perkins Caufield & Byers, TPG Biotech, and Longitude Capital
Other Financing Round (2018): $60M led by Xeraya Capital and Bain Capital
Other Financing Round (2020): $120M supported by Xeraya Capital, Longitude Capital, Endeavour Vision, Asahi Kasei Medical, Bain Capital, and Ally Bridge Group
Other Financing Round (2021): $81M featuring Asahi Kasei Corporation, Sunley House Capital Management, Bain Capital, Adage Capital Management, Xeraya Capital, T. Rowe Price, Longitude Capital, Endeavour Vision, Ally Bridge Group, Quaker BioVentures, BlackRock, D1 Capital Partners, and Caas Capital Management
Debt (2025): $45M backed by Trinity Capital
Key Investors in Rapid Micro Biosystems
Kleiner Perkins Caufield & Byers
A Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology and life science companies, backing founders across consumer, enterprise, healthcare, and climate tech.
TPG Biotech
A global alternative asset management firm with investment strategies spanning private equity and growth equity, partnering with businesses to drive long-term value creation across multiple industries.
Longitude Capital
A healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies, pairing sector expertise with flexible capital to help innovators scale.
What's next for Rapid Micro Biosystems?
With the recent capital injection, Rapid Micro Biosystems is well-positioned to accelerate its market penetration and further scale its global operations. The strategic focus remains on expanding the adoption of the Growth Direct System across diverse pharmaceutical manufacturing environments. As the industry shifts toward more rigorous data integrity standards and faster production cycles, the company's automation technology is expected to become an industry standard. Future growth will likely be driven by continued investment in R&D to address the evolving needs of the cell and gene therapy markets, alongside a commitment to operational excellence across its Swiss, German, and Dutch facilities.
See full Rapid Micro Biosystems company page
